Clinical Trial Update: A Study of the Combination Regimen Grazoprevir (MK-5172) and Elbasvir (MK-8742) ± Ribavirin in Participants With Chronic Hepatitis C (MK-5172-035) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating Grazoprevir and Elbasvir with or without Ribavirin in chronic hepatitis C completed in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Elbasvir (elbasvir)
• Grazoprevir (grazoprevir)
• Ribavirin (ribavirin)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hepatitis C | Phase 2 | Status: COMPLETED | Results posted: 2016-05-30